HHS said it would terminate Women’s Health Initiative, then reconsidered

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.

April 03, 2026

Vol.52 No.13

By Claire Marie Porter

Clinical Roundup

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

HHS said it would terminate Women’s Health Initiative, then reconsidered

YOU MAY BE INTERESTED IN

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

START, Trialing collaborate to expand access to oncology clinical trials across Europe

Renew today!

Subscriber content

Never miss an issue!

Login

HHS said it would terminate Women’s Health Initiative, then reconsidered

YOU MAY BE INTERESTED IN

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside downThe Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

START, Trialing collaborate to expand access to oncology clinical trials across Europe

Never miss an issue!

Login

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”